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Introduction
Since the introduction of nalidixic acid for the treatment of Gram-negative urinary tract infections in 1962, the quinolones have become important and effective agents in the treatment of bacterial infections. Two major groups of compounds have been developed from the basic quinine molecule: the quinolones and naphthyridones. 1 After a slow start, derivatives were developed that had increased potency and improved bioavailability and pharmacokinetic characteristics. However, some of these structural changes have been found to correlate with specific side effects, which resulted in the withdrawal of several agents after marketing or in late development. 2 One of the earliest and most important changes was the addition of a fluorine atom at position 6 of the quinine-based pharmacore; this single alteration provided a large increase in potency, and many currently used fluoroquinolones were derived from this molecule. Of these, ciprofloxacin became the benchmark against which all future quinolones would be measured. However, increasing antibiotic resistance among respiratory pathogens has prompted the introduction of alternative therapeutic options for respiratory infections, most prominent among which are the 'new' fluoroquinolones levofloxacin and moxifloxacin. The new fluoroquinolones possess increased activity against Gram-positive bacteria as well as superior pharmacokinetic/pharmacodynamic properties compared with the older quinolones. 3 An in-depth analysis of quinolone use was performed using a classification based on their pharmacokinetic and in vitro potency profiles, which determine the area of clinical use. This paper reports on outpatient quinolone use in 2009 in Europe, based on the consumption data collected from 33 European countries. It also reviews the seasonal variation, temporal trends and composition of quinolone use in 1997 -2009, focusing in particular on the new so-called respiratory quinolones.
Methods
In 2009, 35 countries were included in the European Surveillance of Antimicrobial Consumption (ESAC) project of which 33 provided valid data. The methods for collecting use data on systemic antibiotics are described elsewhere. 4 For the period 1997 -2009, data on the use of systemic antibiotics for ambulatory care aggregated at the level of the active substance were collected, in accordance with the Anatomical Therapeutic Chemical (ATC) classification and defined daily dose (DDD) measurement unit (WHO, version 2011). 5 To provide a detailed description of outpatient quinolone use in 2009, data are reported as DDD per 1000 inhabitants per day (DID) and packages per 1000 inhabitants per day (PID); the number of DDD per package was calculated by dividing DID by PID values for each country. Quarterly outpatient quinolone use data in DID were statistically modelled to assess seasonal variation and trends in use from 1997 to 2009 for Europe, using longitudinal data analysis. 6 Through compositional data analysis, annual outpatient use data in DID were modelled to assess trends of the relative proportions of the major quinolone subgroups from 1997 to 2009 for Europe. 7 For comparison of outpatient quinolone use, quinolones were classified into three generations, as introduced by Ball, 1 based on their chemical structure and antimicrobial activity (Table 1) . 8 
Results

Outpatient quinolone use in 2009
The WHO Collaborating Centre for Drug Statistics Methodology has assigned 26 unique ATC codes for quinolones, which now include three new compounds (prulifloxacin, pazufloxacin and garenoxacin) not included in earlier descriptions of quinolone use in Europe (Table 1 ). Only five quinolones had .1% of the total outpatient quinolone use in 2009, while no use was recorded for 10 other quinolones (Table 1) . Figure 1 shows the total outpatient quinolone use as well as the relative use of each of the three quinolone generations in 2009 expressed in DID for 32 European countries [including Cyprus and Lithuania with total use data (i.e. both ambulatory and hospital use)] and 2004 data for Switzerland. Outpatient quinolone use varied by a factor of 7.5 between the countries with the highest (3.61 DID in Italy; 4.13 DID in Cyprus is total use data) and lowest (0.48 DID in the UK) use. In 2009, firstgeneration quinolones (mostly norfloxacin) still represented 55% of the total outpatient quinolone use in Croatia, .30% in the Czech Republic, Cyprus, Estonia, Switzerland and Poland, and .10% in all but 11 countries (,10% of total use Belgium, Germany, Luxembourg, Portugal, Sweden, UK; no use in Denmark, Ireland, Norway, Israel and Iceland). Use of firstgeneration quinolones varied from 0.74 DID in Croatia and 1.5 DID in Cyprus (total use) to 0.02 DID in the UK, with no reported use in Denmark, Iceland, Ireland, Israel and Norway. Pipedimic acid was used in 10 countries, DID ranging from 0.001 in Germany to 0.14 in Italy. Among the other first-generation quinolones, nalidixic acid was used in Hungary, the Russian Federation, Romania and the UK (1.8%, 0.2%, 0.1% and 0.04% of total quinolone use, respectively), cinoxacin was used only in Italy (0.4% of total quinolone use) and flumequine was only used in France (0.6% of total use). Second-generation quinolones were by far the most widely used quinolones in Europe, their use Longitudinal data analysis (1997 -2009) A significant increase in total outpatient quinolone use of 0.01 (SD 0.003) DID per quarter was found, starting from 1.11 (SD 0.17) DID in the first quarter of 1997. There was also a significant seasonal variation with an amplitude of 0.06 (SD 0.03) DID, which increased significantly over time by 0.002 (SD 0.0005) DID per quarter ( Figure 3) . Furthermore, the longitudinal analysis showed that both the upward winter and downward summer peaks of outpatient quinolone consumption shifted significantly from one year to another, and that there was a positive correlation between the volume of use and the seasonal variation. This means that, in terms of absolute amounts, high quinoloneconsuming countries tend to have a high seasonal variation in quinolone use and vice versa. Table 2 provides an overview of the quinolone consumption trends in the participating countries between 1997 and 2009. Only two countries (Slovenia and Sweden) showed a decrease in quinolone use over time. The use of quinolones increased by .1 DID in Greece (1.51 DID), Luxembourg (1.18 DID) and Italy (1.08 DID). The seasonal variation in outpatient quinolone use in 12 European countries missing a maximum of 1 year of quarterly data for 1997-2009 is shown in Figure S1 (available as Supplementary data at JAC Online). Data for another 15 countries able to deliver quarterly data for 1997-2009 but missing more than 1 year of data are in Figure S2 (available as Supplementary data at JAC Online). In all countries except Germany, Italy and Luxembourg, mean quinolone use in the first and fourth quarters did not exceed mean use in the second and third quarters by .20%. The high seasonal variation in Germany, Italy and Luxembourg resulted from the relatively frequent use of levofloxacin, moxifloxacin and in Italy also of prulifloxacin in the winter quarters. In most countries seasonal variation was highest for moxifloxacin, except for the Czech Republic, Slovakia and the UK (levofloxacin). However, other quinolones also showed an increase in use in the winter months. Ciprofloxacin variation was .20% in Slovakia and Poland and .15% in Hungary, Latvia and the Russian Federation. Ofloxacin variation was .15% in the Czech Republic, Poland and Slovakia, while norfloxacin variation was .15% in Latvia.
Compositional data analysis (1997 -2009)
For Europe, the relative use of third-generation quinolones significantly increased over time with respect to the use of secondgeneration quinolones, whilst the use of both significantly increased relative to the use of first-generation quinolones Country, total national quinolone use; first, first-generation quinolones; second, second-generation quinolones; third, third-generation quinolones; -, no use reported; 0.00, ,0.005.
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and of the second-generation quinolones in the Czech Republic, Latvia, Norway, Poland, Sweden and Slovakia. In Germany, Spain, France, Hungary, Italy and the Netherlands the initial increase in third-generation quinolones has stabilized or decreased again in favour of second-generation quinolones.
Discussion
This study describes outpatient use in Europe of quinolones (J01M), which has been one of the fastest growing antibiotic classes since the start of the ESAC survey in 1997. 4 There was striking variation in outpatient prescribing, with Italy having the highest outpatient quinolone use (mainly levofloxacin) in 2009, which was part of a continuously increasing trend, and Belgium showing the highest third-generation (mainly moxifloxacin) quinolone use. In Portugal (highest user in 2003) stable total consumption (still mainly ciprofloxacin) was seen, despite a substantial increase in moxifloxacin use since 2002. However, in general the use of quinolones remained highest in Southern Europe, followed by Eastern Europe, and was lowest in Northern Europe. In contrast to total outpatient antibiotic use of all classes of antibiotics, no important shifts in ranking were observed for outpatient quinolone use when using PID as the outcome measure instead of DID (Figure 2 ). This reflects the fact that the number of DDD per package for quinolones shows much less inter-country variation relative to that seen for total outpatient antibiotic use and for the other major antibiotic classes. 4,9 -13 The nomenclature of the quinolones is complex and we again used a classification based on their pharmacokinetic and in vitro potency profiles, which determine the area of clinical use. The increased in vitro potency profiles of newer quinolones has resulted in a shift away from those agents used predominantly for the treatment of urinary tract infections in the 1960s/70s (first-generation quinolones) to quinolones developed in the 1980s/90s and used systemically (second-generation quinolones), through to quinolones used for the treatment of respiratory tract infections in the current millennium (third-generation quinolones). Substantial use (.0.1 DID) of other quinolones was observed only in Italy (prilifloxacin and pipemidic acid) and Portugal (prilifloxacin).
During the 1990s, the use of the second-generation quinolones steadily increased at the expense of the first-generation compounds in most countries. This trend has changed, especially in the countries with the highest quinolone use in Europe, due to the introduction of newer agents such as levofloxacin (second-generation) and moxifloxacin (thirdgeneration). In some countries the proportion of moxifloxacin is continuously increasing, while in Germany, France, Hungary, Spain, Italy and the Netherlands this initial increase was followed by a decrease starting in 2005 -06. It is not clear whether this decrease was initiated by clinicians' changed perceptions of resistance, which is known to influence their choice of antibiotic. 14 In some countries (such as Belgium, Luxembourg and Portugal) these so-called respiratory quinolones (levofloxacin Since in most, if not all, European countries quinolones are not recommended as first-line antibiotics for the treatment of lower respiratory tract infections in ambulatory care, 15 the substantial increase in use of respiratory quinolones in the winter months should ideally not have occurred. Moreover, infections caused by atypical bacteria or pneumococci with intermediate resistance to b-lactam antibiotics can still be successfully treated with high doses of b-lactams. 16 What was more striking is that outpatient use of so-called urinary quinolones with wide activity against Gram-negative bacteria but only marginal activity against Gram-positives also showed an increase in use in the winter months, e.g. ciprofloxacin in Slovakia, Poland, Hungary, Latvia and the Russian Federation. This inappropriate use of both the older and respiratory quinolones will inevitably lead to emergence of resistant pneumococci and also of resistant Gram-negative organisms. 17 That is why seasonal variation of quinolone use is among the final set of ESAC drug-specific quality indicators for outpatient antibiotic use in Europe. 18 The 2009 values for these quality indicators are reported in an accompanying paper. 19 A recent publication listed a set of disease-specific quality indicators for outpatient antibiotic prescribing for the six main indications for antibiotic prescribing (acute otitis media, acute upper respiratory infection, acute/chronic sinusitis, acute tonsillitis, acute bronchitis/bronchiolitis and cystitis/other urinary infection) and for pneumonia. 20 This set was scored by 40 experts from 25 countries, and suggests that for each of these Adriaenssens et al.
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indications quinolones should be prescribed in only 0%-5% of patients prescribed an antibiotic. Using (seasonal) quinolone use as a quality indicator has also been suggested by Altiner et al., 21 and has been implemented already in Scotland. 22 Although quinolones do not represent the first-line therapy for most adult respiratory tract infections in Europe, a substantial change in the prescribing pattern of these agents was noted in the ESAC project. As quinolone use should be restricted and mainly reserved for well-defined indications, such high use probably indicates non-adherence to prescribing guidelines. From a public health perspective, this is an important consideration, as excessive and inappropriate use of quinolones is associated with the development of resistance, requires more resources and exposes patients to the additional risk of side effects.
